Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple additive make eye surgery safer for the heart?

NCT ID NCT07675616

Symptom relief Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This trial tests whether adding dexmedetomidine or magnesium sulphate to lidocaine for a peribulbar block (anesthesia around the eye) helps keep heart rate and blood pressure steady during dacryocystorhinostomy (tear duct surgery) under general anesthesia. Sixty adults undergoing elective surgery will be randomly assigned to receive one of three mixtures. The goal is to find which additive provides better hemodynamic stability, reducing risks like reflex changes in heart rate during surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dexmedetomidine and magnesium sulphate
What this could lead to
If one additive works better, it could become a standard way to keep patients stable during eye surgery under general anesthesia.
What could go wrong
This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. Both additives are already used in other settings, so no major breakthrough is expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status I or II. * Undergoing elective Dacryocystorhinostomy (DCR) surgery under general anesthesia. Exclusion Criteria: * Patients have local infection. * Allergic reaction or complications of the local anaesthesia (LA). * Coagulopathy defined as international normalized ratio (INR) \> 1.5, platelet count \< 100,000/mm³, or ongoing anticoagulant therapy not adequately discontinued. * Uncontrolled systemic disease, defined as poorly controlled hypertension \[systolic blood pressure (SBP) \> 160 mmHg\], uncontrolled diabetes mellitus (HbA1c \> 8.5%), unstable ischemic heart disease, or decompensated hepatic or renal disease. * Uncooperative patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dacryocystorhinostomy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

familial congenital nasolacrimal duct obstruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dacryocystorhinostomy Dexmedetomidine General anesthesia Hemodynamic effect Lidocaine Magnesium sulphate Peribulbar block

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cairo University

    RECRUITING

    Cairo, 12613, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.